Lannett Company, Inc. (NYSE:LCI) has received an average rating of “Hold” from the nine research firms that are covering the company, Marketbeat Ratings reports. Seven analysts have rated the stock with a hold rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $13.56.
A number of brokerages recently issued reports on LCI. Zacks Investment Research upgraded shares of Lannett from a “hold” rating to a “strong-buy” rating and set a $9.75 price target on the stock in a research note on Saturday, February 9th. SunTrust Banks began coverage on shares of Lannett in a research note on Tuesday, March 19th. They issued a “hold” rating and a $9.00 price target on the stock. Finally, ValuEngine cut shares of Lannett from a “hold” rating to a “sell” rating in a research note on Tuesday, April 16th.
In other Lannett news, CEO Timothy C. Crew bought 4,000 shares of the firm’s stock in a transaction on Monday, February 11th. The stock was acquired at an average price of $8.48 per share, with a total value of $33,920.00. Following the transaction, the chief executive officer now owns 45,988 shares in the company, valued at $389,978.24. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Patrick G. Lepore bought 25,000 shares of the firm’s stock in a transaction on Tuesday, February 12th. The stock was acquired at an average cost of $8.93 per share, with a total value of $223,250.00. The disclosure for this purchase can be found here. 12.57% of the stock is currently owned by insiders.
Shares of Lannett stock opened at $7.68 on Friday. The stock has a market capitalization of $335.51 million, a P/E ratio of 2.48 and a beta of 2.40. Lannett has a 1 year low of $3.33 and a 1 year high of $17.15. The company has a current ratio of 2.44, a quick ratio of 1.88 and a debt-to-equity ratio of 2.29.
Lannett (NYSE:LCI) last announced its quarterly earnings results on Monday, May 6th. The company reported $0.68 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.06. The company had revenue of $172.79 million for the quarter, compared to analysts’ expectations of $155.55 million. Lannett had a negative net margin of 39.44% and a positive return on equity of 22.88%. Lannett’s revenue was down .9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.80 EPS. As a group, analysts expect that Lannett will post 2.14 earnings per share for the current fiscal year.
Lannett Company, Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, suspension, soft gel, and injectable dosages.
Recommended Story: What defines an oversold asset?
Receive News & Ratings for Lannett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett and related companies with MarketBeat.com's FREE daily email newsletter.